Medicare Part D plans cover popular obesity drugs if they are used for an additional medically accepted purpose as approved ...

Investors scored big wins last year as the S&P 500, the Nasdaq, and the Dow Jones Industrial Average all climbed by double ...

A Bucks County woman is speaking out after her insurance company decided to no longer cover weight loss drugs.

Eli Lilly trims Q4 guidance but maintains optimism with promising drugs like Zepbound for sleep apnea and global launches ...

Using body-mass index to tell who is overweight or obese is not reliable and can result in misdiagnosis, the Commission on ...

Next to artificial intelligence, weight-loss drugs have been one of the biggest themes investors latched onto in 2024. Eli ...

Eli Lilly (NYSE: LLY) saw its stock decline sharply by 6.5% on January 14, following the release of its fourth-quarter 2024 ...

The BMI, a weight-to-height ratio, has been criticised as too simplistic as it cannot distinguish between fat and muscle mass ...

Leerink Partners analyst Mike Kratky has maintained their neutral stance on INSP stock, giving a Hold rating on January 13.Stay Ahead of the ...

Eli Lilly CEO confirms oral obesity drug Phase 3 results expected in Q2 Eli Lillys CEO updates on drug trials amid mixed ...

An international and widely supported group of experts is pushing doctors to avoid the exclusive use of BMI to decide whether ...